These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27127841)

  • 1. A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers.
    Bendell JC; Zakari A; Lang E; Waterhouse D; Flora D; Alguire K; McCleod M; Peacock N; Ruehlman P; Lane CM; Earwood C; Shih K
    Cancer Invest; 2016 May; 34(5):213-9. PubMed ID: 27127841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
    Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
    Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
    Berruti A; Fazio N; Ferrero A; Brizzi MP; Volante M; Nobili E; Tozzi L; Bodei L; Torta M; D'Avolio A; Priola AM; Birocco N; Amoroso V; Biasco G; Papotti M; Dogliotti L
    BMC Cancer; 2014 Mar; 14():184. PubMed ID: 24628963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
    Castellano D; Capdevila J; Sastre J; Alonso V; Llanos M; García-Carbonero R; Manzano Mozo JL; Sevilla I; Durán I; Salazar R
    Eur J Cancer; 2013 Dec; 49(18):3780-7. PubMed ID: 24012098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
    Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
    Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
    Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
    Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
    Dasari A; Phan A; Gupta S; Rashid A; Yeung SC; Hess K; Chen H; Tarco E; Chen H; Wei C; Anh-Do K; Halperin D; Meric-Bernstam F; Yao J
    Endocr Relat Cancer; 2015 Jun; 22(3):431-41. PubMed ID: 25900182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.
    Yao JC; Guthrie KA; Moran C; Strosberg JR; Kulke MH; Chan JA; LoConte N; McWilliams RR; Wolin EM; Mattar B; McDonough S; Chen H; Blanke CD; Hochster HS
    J Clin Oncol; 2017 May; 35(15):1695-1703. PubMed ID: 28384065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
    Claringbold PG; Price RA; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):561-9. PubMed ID: 23078020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours.
    Koumarianou A; Antoniou S; Kanakis G; Economopoulos N; Rontogianni D; Ntavatzikos A; Tsavaris N; Pectasides D; Dimitriadis G; Kaltsas G
    Endocr Relat Cancer; 2012 Feb; 19(1):L1-4. PubMed ID: 22232542
    [No Abstract]   [Full Text] [Related]  

  • 12. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
    Castellano D; Bajetta E; Panneerselvam A; Saletan S; Kocha W; O'Dorisio T; Anthony LB; Hobday T;
    Oncologist; 2013; 18(1):46-53. PubMed ID: 23263288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
    Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
    Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
    Yao JC; Phan A; Hoff PM; Chen HX; Charnsangavej C; Yeung SC; Hess K; Ng C; Abbruzzese JL; Ajani JA
    J Clin Oncol; 2008 Mar; 26(8):1316-23. PubMed ID: 18323556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
    Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
    Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
    Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
    Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update.
    Bajetta E; Catena L; Pusceddu S; Spada F; Iannacone C; Sarno I; Di Menna G; Dottorini L; Marte AM
    Neuroendocrinology; 2018; 106(4):307-311. PubMed ID: 28743120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
    Yao JC; Lombard-Bohas C; Baudin E; Kvols LK; Rougier P; Ruszniewski P; Hoosen S; St Peter J; Haas T; Lebwohl D; Van Cutsem E; Kulke MH; Hobday TJ; O'Dorisio TM; Shah MH; Cadiot G; Luppi G; Posey JA; Wiedenmann B
    J Clin Oncol; 2010 Jan; 28(1):69-76. PubMed ID: 19933912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on novel therapies for pancreatic neuroendocrine tumors: 2013.
    Dimou A; Syrigos KN; Saif MW
    JOP; 2013 Jul; 14(4):377-80. PubMed ID: 23846931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.
    Yao JC; Phan AT; Chang DZ; Wolff RA; Hess K; Gupta S; Jacobs C; Mares JE; Landgraf AN; Rashid A; Meric-Bernstam F
    J Clin Oncol; 2008 Sep; 26(26):4311-8. PubMed ID: 18779618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.